Pancreatic Cancer Research

ResearcherShandong UniversityActive in the last 2 years

Hanxiang Zhan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8663-2783; OpenAlex author ID A5014616197. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 6 papers · 2022: 3 papers · 2023: 4 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 19

  1. HNRNPC lactylation promotes pancreatic cancer progression through mediating the alternative splicing of PAK6. First author DOI 10.1016/j.canlet.2025.218230↗
  2. ZFHX3 methylation in peripheral blood monocytes as a potential biomarker for pancreatic cancer detection. Last author DOI 10.1016/j.pan.2024.05.529↗
  3. FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3/IL-1β axis. Last author DOI 10.1016/j.canlet.2023.216403↗
  4. Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28. Co-author DOI 10.1038/s41416-023-02313-y↗
  5. KCNH2 regulates the growth and metastasis of pancreatic cancer Co-author DOI 10.1097/jp9.0000000000000123↗
  6. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Co-author DOI 10.3389/fonc.2023.1166860↗
  7. Cancer-associated fibroblast-secreted miR-421 promotes pancreatic cancer by regulating the SIRT3/H3K9Ac/HIF-1α axis. Co-author DOI 10.1002/kjm2.12590↗
  8. LINC00960 regulates cell proliferation and glycolysis in pancreatic cancer through the miR-326-3p/TUFT1/AKT-mTOR axis. Co-author DOI 10.1002/kjm2.12594↗
  9. COL17A1 facilitates tumor growth and predicts poor prognosis in pancreatic cancer. Last author DOI 10.1016/j.bbrc.2022.09.049↗
  10. Macrophages in pancreatic cancer: An immunometabolic perspective. Last author DOI 10.1016/j.canlet.2020.10.029↗
  11. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103271↗
  12. Exosomal linc-ROR mediates crosstalk between cancer cells and adipocytes to promote tumor growth in pancreatic cancer. Last author DOI 10.1016/j.omtn.2021.06.001↗
  13. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.12.077↗
  14. Plasma-Derived Exosome MiR-19b Acts as a Diagnostic Marker for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.739111↗
  15. Neoadjuvant therapy for pancreatic cancer: Limitations and advances of response assessment (Review). First author DOI 10.3892/or.2021.7977↗
  16. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancrea… Co-author DOI 10.1053/j.gastro.2019.10.038↗
  17. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Co-author DOI 10.1016/j.canlet.2017.01.041↗
  18. MicroRNA-195 Suppresses the Progression of Pancreatic Cancer by Targeting DCLK1. Co-author DOI 10.1159/000485876↗
  19. TUFT1 regulates metastasis of pancreatic cancer through HIF1-Snail pathway induced epithelial-mesenchymal transition. First author DOI 10.1016/j.canlet.2016.08.017↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongzheng Li · 5 shared papers, 2021–2024 · strength 0.86
  2. Shanglong Liu · 5 shared papers, 2016–2023 · strength 0.72
  3. Zhiyao Fan · 4 shared papers, 2021–2024 · strength 0.67
  4. Jian Yang · 3 shared papers, 2021–2023 · strength 0.46
  5. Zhaowei Sun · 3 shared papers, 2021–2022 · strength 0.46
  6. Jianwei Xu · 4 shared papers, 2016–2021 · strength 0.46
  7. T. T. Qu · 3 shared papers, 2022–2023 · strength 0.44
  8. Jing‐Hao Lei · 3 shared papers, 2022–2023 · strength 0.44
  9. Chuanxin Wang · 2 shared papers, 2023–2026 · strength 0.44
  10. Sanyuan Hu · 3 shared papers, 2017–2021 · strength 0.37
  11. Weidong Guo · 3 shared papers, 2016–2022 · strength 0.34
  12. Min Li · 3 shared papers, 2020–2021 · strength 0.30
  13. Zhijun Zhou · 3 shared papers, 2020–2021 · strength 0.30
  14. Jingxuan Yang · 3 shared papers, 2020–2021 · strength 0.30
  15. Courtney W. Houchen · 3 shared papers, 2020–2021 · strength 0.30
  16. Jingyu Cao · 2 shared papers, 2022 · strength 0.28
  17. BoHao Li · 1 shared paper, 2026 · strength 0.28
  18. Yangmiao Duan · 1 shared paper, 2026 · strength 0.28
  19. Bin Zhou · 3 shared papers, 2016–2022 · strength 0.28
  20. Guangyong Zhang · 2 shared papers, 2017–2023 · strength 0.27
  21. Yuanyuan Jiang · 2 shared papers, 2021–2022 · strength 0.26
  22. Lei Wang · 2 shared papers, 2017–2021 · strength 0.25
  23. Ying Li · 1 shared paper, 2023 · strength 0.22
  24. Jing Wang · 1 shared paper, 2023 · strength 0.22
  25. Xiuhui Shi · 2 shared papers, 2021 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.